Article Information
History
- February 22, 2019.
Article Versions
- You are currently viewing Version 1 of this article (February 22, 2019 - 16:06).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Chuan Liu1 (chuanliu2005{at}163.com),
- Scott Leighow2 (sml94{at}psu.edu),
- Haider Inam2 (hzi14{at}psu.edu),
- Boyang Zhao2 (quantalarity{at}gmail.com) and
- Justin R Pritchard2,3 (jrp94{at}psu.edu)
- 1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;
- 2 Pennsylvania State University
- ↵* Corresponding author; email: jrp94{at}psu.edu
Posted February 22, 2019.
Exploiting the 'survival of the likeliest' to enable evolution-guided drug design
